Clinical trials: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells.
- Conditions
- Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
- Trial name
- NCT03225144
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis)
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
- Conditions
- Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
- Trial name
- NCT07543367
- Testing
- Stentrode
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Background: Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time.
- Trial name
- NCT07204977
- Testing
- Acamprosate calcium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, ALS
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
- Trial name
- NCT05163886
- Testing
- LAM-002A
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IRulya Therapeutics Inc.
Amyotrophic Lateral Sclerosis (ALS)
Developing New Ways to Detect Respiratory Impairment Early in ALS
The goal of this observational study is to develop new ways to detect early changes associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- Trial name
- NCT07844590
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Background: Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat itself thousands of times.
- Trial name
- NCT01925196
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Nervous System Diseases, Spinal Cord Diseases
- Trial name
- ALS-LTMV (NCT05744310)
- Testing
- Long term mechanical ventilation support, No long term mechanical ventilation support
- Where
- 9 sites in Norway
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
ALSFTD, ALS (Amyotrophic Lateral Sclerosis)
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants…
- Conditions
- ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
- Trial name
- PROBIOTIC (NCT06051123)
- Testing
- Probiotic
- Where
- 3 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition
The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative…
- Trial name
- TDP-signatures (NCT07796776)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
ALS (Amyotrophic Lateral Sclerosis)
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited.
- Trial name
- UNZUELUZON ALS (NCT07737977)
- Testing
- peripheral venous blood collection, collection of medical data related to patient care
- Where
- 2 sites in France, Spain
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders
Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease, often difficult to diagnose due to symptoms similar to other neurological pathologies.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Neurodegenerative Disorders, Motor Neuron Diseases
- Trial name
- DIAGONALS (NCT07706270)
- Testing
- Serum Neurofilament Serum NfL Measurement
- Volunteers
- 138 people
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis, ALS
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
- Trial name
- ALSFUS003 (NCT07193953)
- Testing
- Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Sunnybrook Health Sciences Centre
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset).
- Trial name
- ASTRALS (NCT06643481)
- Testing
- VHB937
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, ALS
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS.
- Trial name
- NCT04259255
- Testing
- Edaravone (Radicava®/Radicava ORS®)
- Where
- 20 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Assessment of Speech and Fine Motor Control in ALS
This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- NCT06315673
- Testing
- Digital Speech and Handwriting Assessment
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND)
Healing ALS Registry Observational Study (HAROS)
This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study).
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS)
- Trial name
- HAROS (NCT07233148)
- Testing
- Education about treatment options, Dietary Supplements: Vitamins, Minerals, Herbs, etc., Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc.
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Healing Advocates Registry and Ministry
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02327845
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Miami